Imaging surveillance of differentiated thyroid cancer

Abstract

Intensive imaging surveillance has resulted in the ability to detect small-volume, often clinically occult, residual or recurrent disease. For most patients with differentiated thyroid cancer (DTC), such findings are unlikely to have an impact on disease-specific survival but our ability to predict which patients are at greatest risk and should receive the most aggressive therapies is surpassed by our ability to detect recurrence. Thus, the optimal treatment and surveillance regimens will surely continue to evolve as our ability to predict tumor behavior and aggressiveness improves. This article explains the rationale underlying current surveillance strategies and the utility and implications of imaging findings that are critical for the appropriate care of patients with DTC.